In this Issue:
• Come September- Historically, stocks have been weak in the final month
of the third quarter. Was 2004 an anomaly?
• In the Limelight
• STARS Status - Changes in S&P analysts' STARS rankings for August 22 through August 26.
• Tribune on Track, Dow Jones Faces Hurdles- In this side-by-side comparison, we explain why we favor one of these media companies over the other.
• Favored A+ Stocks- The stocks in the table on page 7 have a solid history of growth and stability of earnings and dividends, and our analysts expect them to outperform over the coming year.
• Why We Are Bullish on Biotech- Biotechnology has been one of the market's hottest industries this summer, and Standard & Poor's does not expect the group to cool off as we move into 2006.
• Master List Stock Update- Our three supervised Master List groups of stocks, recommended as core holdings for long-term investors, are regularly featured on these two pages. Group 3, highlighted this week, consists of small- and mid-cap stocks.
• Neural Fair Value 25 Portfolio- This portfolio of 25 stocks seen as undervalued is expected to significantly outperform the S&P 500.

Some of the Companies Featured:
Allmerica Financial
Amis Holdings
Autozone
Chattem Inc.
Cintas Corp.
Constellation Brands Inc.
Donaldson Co.
Goldman Sachs
M.D.C. Holdings Inc
Merck
Odyssey Healthcare
Six Flags
Synnex Corp.
Target Corp.
Toro Co.
Vail Resorts
Wellcare Health Plans Inc.
Wpp Group

S&P Information Products

Browse S&P industry research products by category:

S&P Industry Surveys
S&P Industry Stock Reports
The Outlook
Search Engine Survey
Pocket Guides
Power Picks

About Standard & Poor's

Standard & Poor's is one of the world's preeminent providers of credit ratings, and for such globally recognized financial-market indices as the S&P 500®. S&P also provides a wide range of other products and services designed to help individuals and institutions around the world make better-informed financial decisions with greater confidence.